Dulaglutide to Orforglipron Dose Conversion Guide
Medically reviewed by Lauren Okafor | MD, The Frank H Netter MD School of Medicine, Loyola University Medical Center on July 21st, 2026.
Published on July 22nd, 2026. Updated on July 22nd, 2026.
Key takeaways
No validated 1:1 dose conversion chart exists for dulaglutide to orforglipron, so clinicians typically restart titration from the lowest orforglipron dose regardless of prior injectable dose.
Dulaglutide has an approximate 5-day half-life, meaning starting orforglipron too soon after the last injection could create an overlap in drug activity.
Glycemic control may temporarily worsen during the first 2 to 4 weeks of orforglipron titration as the new medication builds toward full efficacy.
GI side effects like nausea can reappear even in patients who previously tolerated dulaglutide well, due to differences in how the oral drug is absorbed.
Medical supervision is especially important for patients on insulin, sulfonylureas, or those with kidney disease or heart failure during this transition.
What Makes This Conversion Clinically Unique
Dulaglutide and orforglipron both activate the GLP-1 receptor, but they are fundamentally different kinds of molecules. Dulaglutide is a weekly subcutaneous injectable peptide, while orforglipron is a daily oral non-peptide GLP-1 receptor agonist. This distinction matters enormously when planning a transition.
Because the two agents belong to different molecular classes with distinct absorption pathways and pharmacokinetic profiles, their plasma exposure curves simply do not map onto each other. As of 2025, no published 1:1 dose equivalency table exists. Clinicians must rely on titration principles rather than fixed conversion ratios, which means the switch requires more planning than a straightforward dose substitution.
Understanding this upfront helps patients set realistic expectations and avoid the assumption that staying at a "similar" dose level will automatically maintain their current level of blood sugar or weight management.
Comparing the Two Medications Side by Side
The table below outlines the key differences between dulaglutide and orforglipron across several clinically relevant features.
Feature |
Dulaglutide |
Orforglipron |
|---|---|---|
Route of administration |
Subcutaneous injection |
Oral tablet |
Dosing frequency |
Once weekly |
Once daily |
Approved dose range |
0.75 mg to 4.5 mg weekly |
3 mg to 36 mg daily (Phase 3 studied) |
Molecular class |
Peptide GLP-1 receptor agonist |
Non-peptide GLP-1 receptor agonist |
Half-life |
Approximately 5 days |
Shorter, oral kinetics |
GI side effect pattern |
Nausea common during titration |
Nausea possible, concentrated by oral absorption |
Established 1:1 conversion |
Not applicable |
No validated conversion chart exists |
Dulaglutide's dose range spans from 0.75 mg weekly for new starters up to 4.5 mg weekly at maximum approved doses. Orforglipron Phase 3 trials studied doses of 3 mg, 12 mg, 24 mg, and 36 mg daily, with patients titrating upward gradually over weeks. While there is some rough conceptual alignment between lower dulaglutide doses and early orforglipron titration targets, these comparisons are not interchangeable in a clinical sense.
How Clinicians Approach the Transition
The general clinical principle when switching from dulaglutide to orforglipron is to stop the injectable, allow an appropriate gap, and then begin orforglipron at its lowest available titration dose. This approach applies regardless of how high the patient's dulaglutide dose was prior to switching.
The rationale for restarting at the bottom of the orforglipron titration ladder involves several factors. First, there is no cross-tolerance data to support skipping titration steps. Second, the different receptor engagement kinetics of oral versus injectable GLP-1 agents mean that GI tolerability essentially resets. Third, starting low and going slow remains the standard safety approach for this drug class.
Timing also matters considerably. Dulaglutide has an approximate 5-day half-life. If orforglipron is initiated within the same week as the final dulaglutide injection, there is a real risk of overlapping drug activity, which could intensify side effects or complicate glycemic monitoring. Most clinicians will advise waiting until dulaglutide activity has substantially cleared before introducing the oral agent.
Glycemic and Weight Expectations During the Switch
Patients should be prepared for a transitional period lasting roughly 2 to 4 weeks where GLP-1 receptor coverage may be lower than they were used to on dulaglutide. During this window, fasting glucose may creep upward and postprandial blood sugar spikes may become more noticeable. This is not a sign that orforglipron is failing. It reflects the gradual nature of dose titration.
Orforglipron Phase 3 data showed promising outcomes at higher doses, including HbA1c reductions of up to 1.5 percentage points and weight loss of up to 16% in certain study populations. These results are comparable to injectable GLP-1 agents at full therapeutic doses. However, reaching that level of efficacy may take 8 to 16 weeks of careful titration.
Patients and their care teams should set a realistic timeline and schedule glucose monitoring check-ins during the transition, particularly in the first month.
Side Effect Profile Differences to Anticipate
Both dulaglutide and orforglipron share a familiar GI side effect profile, including nausea, vomiting, and diarrhea. However, oral delivery concentrates the drug's early exposure along the gastrointestinal tract in a way that subcutaneous injections do not. This means patients who tolerated dulaglutide quite well may still experience renewed nausea when beginning orforglipron, particularly in the first few weeks.
For patients on combination therapy that includes insulin or sulfonylureas, dose adjustments may become necessary during the transition. The temporary reduction in GLP-1 activity during titration can shift insulin sensitivity enough to require recalibration of background or mealtime insulin doses.
Tracking symptoms in a simple diary during the first 4 to 6 weeks can give both patients and their providers useful information for making timely adjustments.
When Medical Supervision Is Essential
Self-directed switching from dulaglutide to orforglipron carries meaningful risks. Without medical guidance, patients may inadvertently overlap drug activity, skip titration steps, or misinterpret worsening glucose numbers as treatment failure when it is actually a normal part of the transition process.
Certain patients need especially individualized transition planning. Those with chronic kidney disease face specific considerations around drug clearance and hypoglycemia risk. Patients with heart failure or those on sulfonylureas require careful monitoring during the crossover period. Older adults and those managing multiple medications may need more frequent follow-up than the average patient.
Doctronic offers free 24/7 AI consultations that can help patients understand their specific situation, identify potential drug interaction concerns, and organize questions before meeting with a physician. With over 22 million AI consultations completed and 99.2% treatment plan alignment with board-certified physicians, it serves as an accessible and trustworthy first step for patients navigating a medication change like this one.
Frequently Asked Questions
No validated 1:1 dose conversion chart currently exists as of 2025. Because dulaglutide and orforglipron are fundamentally different molecules with distinct pharmacokinetics, clinicians guide the transition using titration principles rather than fixed dose ratios. Your doctor will determine the safest starting point based on your individual history.
Most clinicians recommend stopping dulaglutide before beginning orforglipron. Because dulaglutide has an approximate 5-day half-life, starting orforglipron within the same week as your last injection may create drug overlap. Your provider can advise on the appropriate timing window to minimize that risk for your specific situation.
Some temporary weight fluctuation is possible during the 2 to 4 week titration period when GLP-1 coverage may be lower. However, Phase 3 data suggest orforglipron at higher doses may produce weight loss comparable to injectable GLP-1 agents. Full efficacy typically emerges over 8 to 16 weeks of careful dose titration.
Orforglipron's full effects may take 8 to 16 weeks to emerge as the dose is gradually increased from the starting level. During the early titration phase, patients may notice less glucose control compared to their prior injectable regimen. Monitoring blood sugar closely during this window is strongly recommended.
Self-directed switching is not recommended. Without medical guidance, patients risk glycemic instability, drug activity overlap, and missed titration steps. Patients with comorbidities like kidney disease or those on insulin face additional risks. A clinician or an AI-assisted consultation can help you prepare a safe, personalized transition plan.
The Bottom Line
Switching from dulaglutide to orforglipron is not a simple formula. There is no published 1:1 dose equivalency, and the safest approach is a clinician-guided titration restart beginning at the lowest orforglipron dose. Patients should anticipate a transitional period of potentially reduced glycemic coverage, possible renewed GI side effects, and gradual dose escalation over weeks. Doctronic, the first AI legally authorized to practice medicine in Utah, offers free 24/7 AI consultations backed by 99.2% treatment plan alignment with board-certified physicians, giving patients a trusted starting point to understand their options and prepare for a physician visit. This article is informational and is not a medical diagnosis. Confirm with a licensed clinician, especially for new, worsening, or high-risk symptoms.
Related articles
Get dulaglutide dosing guidance
Chat Now